8-K: Regenerex Pharma Appoints Kenneth W. Perry as CFO, Brent Wilson Resigns
Current Report
Regenerex Pharma announces the appointment of Kenneth W. Perry as Chief Financial Officer, effective March 31, 2025, following the resignation of Brent Wilson due to personal reasons.
Summary
- Regenerex Pharma, Inc. has appointed Kenneth W. Perry as its new Chief Financial Officer, effective March 31, 2025.
- Mr. Perry brings 39 years of experience in healthcare finance, revenue cycle management, supply chain operations, and information technology.
- He has previously served as Division CFO for HCA and founded Lasis Healthcare.
- Brent Wilson resigned from his position as Chief Financial Officer, effective March 31, 2025, due to personal reasons.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard corporate governance announcement. The appointment of an experienced CFO is generally positive, but the resignation introduces some uncertainty.
Positives
- Regenerex Pharma has appointed a seasoned CFO, Kenneth W. Perry, with extensive experience in healthcare finance.
- Mr. Perry's expertise spans system implementations and strategic leadership, potentially benefiting the company's financial performance.
Industry Context
Changes in key management positions are common in the pharmaceutical industry, often reflecting strategic shifts or the need for specific expertise.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Brent Wilson | Kenneth W. Perry | March 31, 2025 | Personal reasons (Wilson's resignation) |
Stakeholder Impact
- Shareholders may react to the change in CFO, depending on their perception of the new appointment.
- Employees in the finance department may experience changes in leadership and direction.
Key Dates
| Date | Description |
|---|---|
| March 31, 2025 | Kenneth W. Perry appointed as Chief Financial Officer, and Brent Wilson resigned from his position. |
| April 2, 2025 | Date of the report signed by Gregory Pilant, Chairman and CEO. |
Keywords
Chief Financial Officer, CFO, Regenerex Pharma, Appointment, Resignation, Healthcare Finance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.